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Abstract 
Ribonucleic acids (RNAs) are considered as effective and minimally invasive biomarkers for disease 
diagnosis and prognosis due to their critical role in the regulation of different cellular processes. Over the 
past several years, the rapid progress in RNA biomarker research has resulted in the development of a 
large number of high-performance RNA-detection methods. Most of these methods are based on 
molecular-biology techniques such as quantita-tive reverse transcription polymerase chain reaction (RT-
qPCR), microarrays, and RNA sequencing. In recent years, considerable attention has also been dedicated 
to developing RNA biosensors, exploiting micro- and nanofabrica-tion technologies, and various readout 
strategies, including electrochemical and optical transducers. Here, the recent developments of RNA 
biosensors are concisely reviewed with a special emphasis on electrochemical-detection approaches. 
The following points are also highlighted: i) all the types of clini-cally relevant RNAs (mRNAs, miRNAs, 
lncRNAs) and their diagnostic and prognostic potential in cancer are outlined, ii) major challenges 
associated with current techniques are identified, followed by a critical analysis of how these challenges 
have been addressed by different biosensing approaches, and iii) the current requirements that still need 
to be met for effective screening of RNA biomarkers in both research and clinical settings. 
Keywords 
developments, electrochemical, biosensors, diagnostic, rna, prognostic, biomarkers:, potentials, recent 
Disciplines 
Engineering | Physical Sciences and Mathematics 
Publication Details 
Islam, M., Masud, M. Kamal., Haque, M. Hakimul., Hossain, M. Al., Yamauchi, Y., Nguyen, N. & Shiddiky, M. 
J. A. (2017). RNA Biomarkers: Diagnostic and Prognostic Potentials and Recent Developments of 
Electrochemical Biosensors. Small Methods, 1 (7), 1700131-1-1700131-20. 
Authors 
Md Nazmul Islam, Mostafa Kamal Masud, Md Hakimul Haque, Md. Shahriar Al Hossain, Yusuke 
Yamauchi, Nam-Trung Nguyen, and Muhammad J. A Shiddiky 
This journal article is available at Research Online: https://ro.uow.edu.au/aiimpapers/2631 
REVIEW
1700131 (1 of 20) © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-methods.com
RNA Biomarkers: Diagnostic and Prognostic Potentials and 
Recent Developments of Electrochemical Biosensors
Md Nazmul Islam, Mostafa Kamal Masud, Md Hakimul Haque, 
Md Shahriar Al Hossain, Yusuke Yamauchi, Nam-Trung Nguyen, 
and Muhammad J. A. Shiddiky*
DOI: 10.1002/smtd.201700131
1. Introduction
Ribonucleic acid (RNA) biomarkers com-
prising different coding and noncoding 
transcriptome such as messenger RNA 
(mRNA), microRNA (miRNA), and long 
noncoding RNA (lncRNA) are becoming 
progressively crucial in understanding 
disease diagnosis and prognosis due to 
their recognized physiological role in gene 
expression and regulation.[1–9] Dysregula-
tion of these RNA biomarkers is involved 
in the initiation and progression of several 
diseases including cancers.[2,10–15] Among 
the different types of RNAs, protein-
coding RNAs are exclusively represented 
by mRNAs where aberrant mRNA expres-
sion could initiate cancer by altering the 
DNA methylation pattern and different 
cellular regulatory pathways such as chro-
matin modifications, cell adhesion, and 
cell cycles.[5,8] A number of recent studies 
have reported a strong correlation between 
aberrantly expressed mRNA levels and 
various cancers including breast cancer,[16] 
lung cancer,[17] malignant melanoma,[18] and hepatocellular 
carcinoma.[19] During mRNA biogenesis (i.e., transcription), 
mature mRNA is produced from pre-mRNA transcripts via a 
splicing process (i.e., introns removal from nascent RNA fol-
lowed by the joining of exons).[20,21] Any alterations in this 
splicing pattern, referred to as “alternative splicing”, may 
trigger the production of miscellaneous mRNA isomers, which 
further generates diverse protein variants including onco-
proteins.[2,21,22] For example, alternatively spliced Fas mRNA 
isoform (exon 6 is missing) produces a soluble deregulatory 
protein known as sFas which triggers abnormal cell prolifera-
tion in cancer.[2,23]
These protein-coding mRNA genes represent only a 
small percentage of the total genome. On the contrary, more 
than 90% of the genomic DNA generates noncoding RNAs 
(ncRNAs), consisting of housekeeping (e.g., ribosomal RNA, 
transfer RNA) and regulatory noncoding RNAs (e.g., miRNA 
and lncRNA).[24] In recent years, research focus has mostly been 
shifted toward discovery and translational studies of biomarkers 
based on miRNAs (19–25 bases) and lncRNAs (200 bases to 
100 kilobases), due to their strong ability in regulating the gene 
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expression.[4,10,25] These RNAs do not take part in protein pro-
duction (i.e., translation) but they actively regulate the post-tran-
scriptional gene expression and remodeling of the epigenome 
(i.e., DNA methylation and histone modification).[26,27] They 
are crucial for a range of controlled biological processes such 
as cell cycle regulation, pluripotency, retrotransposon silencing, 
etc. These controlled processes may be affected and eventually 
could contribute to cancer development when the sequences of 
noncoding RNAs have anomalies such as copy number varia-
tions, single nucleotide polymorphism, and mutations.[3,14] For 
instance, it has been reported that dysregulated lncRNA, HOX 
transcript antisense RNA (HOTAIR), interacted with polycomb 
repressive complex 2 (PRC2) complex and actively involved in 
the progression of liver and breast cancer,[25] whereas MALAT1 
B7 lncRNA affected the RNA splicing functions and triggered 
several types of cancers such as breast, lung, uterus, pancreas, 
colon, prostate, and liver cancer.[25,28–30]
Until now, nucleic-acid-detection-based techniques such 
as quantitative reverse transcription polymerase chain reac-
tion (RT-qPCR),[31,32] microarrays,[33,34] and RNA sequencing 
methods,[4,35] have widely been applied for the effective analysis 
of RNA levels. These methods typically require some forms of 
amplification steps, cumbersome sample pretreatment proce-
dure, and expensive instrumentation. Additionally, they often 
cannot amplify RNA sequences without a poly(A) tail due to 
the use of oligo(dT) primers for the amplification purpose.[36] 
Additionally, relatively large sample volumes are required for 
sensing RNA biomarkers in body fluids to avoid sample het-
erogeneity, resulting from distinct physiological and systemic 
differences of clinical samples.[37] In this regard, a great deal of 
research has been carried out to find relatively robust, accurate, 
and effective methods, leading to several nanotechnology-based 
RNA sensing approaches coupled with optical and electro-
chemical readouts. These approaches offer relatively easy sam-
pling procedures, rapid and cost-effective analysis, portability, 
label-free and amplification-free options.[38–42] Among these 
methods, electrochemical methods have evidently achieved the 
ultrahigh sensitivity and selectivity with the high potential for 
multiplexed analysis in point-of-care platform.[40,43,44] However, 
the functionality of electrochemical RNA sensors is still con-
fined in the proof-of-concept studies and several challenges are 
yet to be addressed to transform the technologies into routine 
clinical applications.[37]
Here, we review the recent developments of RNA bio-
sensing approaches, especially electrochemical approaches. 
The diagnostic and prognostic roles of RNA biomarkers are 
briefly discussed, followed by a specific discussion on current 
requirements that still need to be met for screening of RNA 
biomarkers in both research and clinical settings. We have 
also highlighted the major technical and biological challenges 
involved in the existing RNA detection strategies and provided 
suggestions for the future direction of the field.
2. RNA Biogenesis
The rate and extent of RNA biogenesis in the nucleus and their 
subsequent role in protein synthesis or gene regulation are sub-
jected to several finely controlled pathways driven by various 
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cellular factors and enzymes.[45–47] mRNA is synthesized in the 
nucleus from the DNA template of a target gene via a process 
known as “transcription.” The transcription process is catalyzed 
by a large molecular enzyme referred to as RNA polymerase II 
(RNA Pol II). RNA Pol II recognizes and binds to the promoter 
site of the template DNA with the help of a group of proteins 
known as general transcription factors (GTFs).[48] First, GTFs 
(e.g., TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) assemble 
near the template DNA and assist RNA Pol II to recognize 
and bind the specific promoter region of the DNA thereby 
forming the preinitiation complex (PIC). The PIC then recruits 
DNA helicases, which facilitate DNA to expose their template 
strand for the initiation of RNA synthesis. After the initiation 
of transcription, the PIC leaves the template strand and RNA 
Pol II starts the elongation process and transcribes hundreds 
of kilobases of pre-mRNA transcripts. After that the RNA Pol 
II is dissociated from DNA template and started re-initiation 
of downstream transcription pathways.[45,46,49] The resultant 
nascent pre-mRNA undertakes three major processing steps to 
form mature mRNAs, which usually occur co-transcriptionally 
(i.e., transcription and pre-mRNA processing happens simulta-
neously). These steps are 5′ capping, splicing and 3′ adenyla-
tion.[45,50] Upon completion of the processing steps, mature 
mRNA is packaged inside a complex consisted of RNA binding 
proteins and other export factors.[45] Then this complex is trans-
ported from the nucleus to cytoplasm through the nuclear pore 
complex which spans over the nuclear envelope (NPC) for fur-
ther activities.[45]
Similarly, miRNAs are synthesized in the nucleus by the 
same transcriptional machinery of mRNA biogenesis.[51] How-
ever, after their export into the cytoplasm, they skip the protein 
synthesis steps and keep a role in gene regulation.[37,52] During 
miRNA biogenesis (Figure 1), miRNA genes are first converted 
to hairpin-structured primary miRNA (pri-miRNA) by either 
RNA pol I or II via transcription process. Pri-miRNAs are then 
cleaved and processed by a distinct protein complex known as 
the microprocessor complex, which consists of ribonuclease 
enzyme Drosha and RNA binding protein DGCR8 (also known 
as pasha). In the next step, the miRNAs are then exported to the 
cytoplasm and further cleaved by Dicer (an enzyme from RNase 
III family) to form miRNA duplexes. Following strand separa-
tion of the duplexes, mature miRNAs are produced, which start 
to accumulate various proteins and enzymes to form RNA-
induced silencing complex (RISC). miRNA exerts its inhibitory 
and regulatory action via RISC-induced RNA degradation and 
post-translational inhibition.[52] Although many aspects of the 
lncRNA biogenesis pathways are relatively less understood, it 
has been reported that the key processes involved in most of 
the recently discovered lncRNAs follow the common mRNA 
biogenesis pathway.[51,53] However, a few other alternative path-
ways for the biogenesis of lncRNAs have been described, which 
employ another type of polymerase enzyme known as RNA pol 
III at the gene promoters and do not undergo a polyadenylation 
processing step.[51,54]
3. Diagnostic and Prognostic Roles of RNA
RNAs are the key regulators of gene expression network and 
involved in controlling cell-cycle, cell proliferation, differen-
tiation, apoptosis, metabolism, and post-transcriptional path-
ways.[2–6,8] Dysregulated RNAs can affect one or several of 
these cellular pathways, resulting in tumor initiation and pro-
gression. Thus, they can be used in diagnosis, prognosis, and 
Small Methods 2017, 1, 1700131
Figure 1. Schematic overview of miRNA biogenesis and regulation pathways. In the nucleus, miRNA genes are first transcribed to hairpin-structured 
pri-miRNA by RNA Pol. Next, microprocessor complex (Drosha and DGCR8) cleaves pri-miRNA to produce pre-miRNA, which is exported to the cyto-
plasm. In the cytoplasm, further cleavage by Dicer results in the formation of miRNA duplexes. Following strand separation of the duplexes, the mature 
miRNAs accumulate into RISCs to exert the regulatory function. Reproduced with permission.[37] Copyright 2015, John Wiley and Sons.
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therapy monitoring of cancers.[5,55,56] Although the specificity 
and reproducibility of circulating miRNA biomarkers is a sub-
ject to recent contradictory discussion (see Section 3.3), they 
offer several distinct advantages such as early detection, high 
stability, and ability to work as liquid biopsy for minimally inva-
sive monitoring of cancer.
Early Detection: A number of studies have confirmed that 
RNA biomarkers have important clinical implications as the 
early indicator of cancer.[17,18,57–62] This is mostly due to the fact 
that during the early development of tumor cells, they release 
significant amounts of RNA into the blood circulation and 
mostly being upregulated. For example, miR-200 was reported 
as an effective biomarker for the early detection of ovarian 
cancer.[63]
High Stability of Circulating miRNAs: Compared to mRNAs 
and lncRNAs, miRNAs have significantly higher stability in a 
clinical sample and can show robust expression pattern.[3,37,55,62] 
Several studies have shown that circulating miRNAs are 
resistant to the degradation by RNases and also unaffected in 
extreme condition such as freeze–thawing, long-term storage, 
high pH, and temperature. This high stability can be explained 
by the fact that they are well protected inside the microvesicles 
such as exosomes and apoptotic bodies, or attached with RNA-
binding proteins.[63–65]
Circulating Biomarker for Minimally Invasive Detection of 
Cancers: Current techniques for cancer diagnosis commonly 
require invasive tissue biopsy, which is not always clinically 
feasible and associated with pain.[66] However, tumor-specific 
circulating RNAs (miRNAs) available in accessible biological 
fluids such as serum, plasma, urine, saliva could bypass the 
need of tissue biopsy.[3,57,67,68] In 2010, Weber et al.[69] assessed 
12 different body fluids including urine, saliva, plasma, tears, 
breast milk, peritoneal fluid, pleural fluid, seminal fluid, amni-
otic fluid, bronchial lavage, cerebrospinal fluid, and colostrum 
and showed that miRNAs are present in these body fluids. This 
wide distribution of miRNA in most biological fluids makes 
them a promising circulating biomarker for less or noninvasive 
diagnosis and more personalized monitoring of diseases.[66] 
The prominent features of using miRNAs as a circulating bio-
marker are that they are minimally painful, and allow clinicians 
to quickly assess disease development and response to thera-
peutics.[70] For example, Debernardi et al.[71] showed a nonin-
vasive profiling of cell-free miRNAs extracted from the urine 
of patients with pancreatic ductal adenocarcinoma and chronic 
pancreatitis can efficiently differentiate the early and late stage 
tumors.
3.1. Diagnostic Roles
Different types of cancers have distinctive signature of mRNA 
expression pattern. For example, Miura et al.[17] demonstrated 
that the expression of human telomerase reverse transcriptase 
(hTERT) mRNA and epidermal growth factor receptor (EGFR) 
mRNA were associated with lung cancer metastasis. In this 
study, real-time RT-PCR was used to measure the serum 
hTERT mRNA and EGFR mRNA levels from 112 patients 
with lung cancer and 80 normal individuals. The levels of 
the mRNAs were significantly interrelated with tumor size, 
number, metastasis, and recurrence in lung cancer which 
elucidated hTERT and EGFR mRNA’s role as diagnostic bio-
marker for lung cancer. Several other mRNAs were reported 
as the diagnostic indicators of epithelial ovarian cancer (EOC) 
due to their specific expression patterns in EOC. For instance, 
p53, BCL-2, BAX mRNAs are downregulated in EOC while 
ASAP1 mRNA is overexpressed.[72,73] A genome wide analyses 
of mRNA expression in 136 breast cancer patients performed 
via RNA sequencing (RNA-seq) also showed that a number of 
32 mRNAs can sensitively act as the diagnostic biomarkers for 
breast cancer.[74]
Alternative splicing can also trigger the production of aber-
rant mRNA isomers leading to the progression of many diseases 
including cancer.[21] This could happen due to the mutations in 
the components of splicing machineries.[11] A number of tumor-
specific alternative splicing events have been reportedly consid-
ered as the effective diagnostic markers and therapeutic targets 
in different cancers such as breast and lung cancer.[75,76] Addi-
tionally, mRNA fusion, which is usually generated from gene 
fusion during aberrant chromosomal rearrangement events, 
have emerged as the new class of sensitive and specific diag-
nostic biomarkers for many cancers. For instance, TMPRSS2-
ERG and BCR-ABL mRNA fusions have been used as diagnostic 
markers for prostate cancer[59] and leukemia,[77] respectively.
In recent years, much attention has been dedicated to 
explore the diagnostic significance of miRNAs in cancer.[3,10,78] 
In 2002, Calin et al.[79] drew a relationship between cancer- and 
tissue-derived miRNA where it was demonstrated that miRNA 
cluster miR 15/16 was downexpressed in chronic lymphocytic 
leukemia. In a large cohort study, Volinia et al.[80] screened 
540 tumor samples derived from lung, breast, stomach, pros-
tate, colon, and pancreas cancers, and identified 43 dysregu-
lated miRNAs as diagnostic biomarkers. Later, in 2008, the 
diagnostic role of circulating miRNA in B-cell lymphoma was 
reported by Lawrie et al.[81] This study reported that the levels 
of miR-21 and miR-155 were significantly higher in the serum 
sample derived from cancer patients compared to that of normal 
sample. Since then, an increasing number of cancer-related cir-
culating miRNA have been identified and studied.[3,10,82] For 
example, Zhou et al.[82] showed the positive diagnostic potential 
of a group of circulating miRNAs (miR-122, miR-192, miR-21, 
miR-223, miR-26a, miR-27a, and miR-801) in a hepatocellular 
carcinoma (HCC) patient sample. In recent times, there is also 
an increasing interest on lncRNAs’ research due to their wide 
biological functions and diagnostic potential.[12,25,60,83] Among 
different lncRNAs, dysregulated HOTAIR is of great interest 
due to their robust expression pattern and active involvement 
in the prognosis, metastasis, and recurrence of a range of can-
cers.[13,25,60,83,84] For example, Gupta et al.[84] showed that the 
rate of HOTAIR transcription in metastatic breast cancer was 
almost 2000-fold raised compared to that of control. This signif-
icantly elevated levels of HOTAIR in cancer cells demonstrates 
their high diagnostic potential.
3.2. Prognostic Roles
Aberrant mRNAs have also been considered as a good indicator 
to predict and track tumor prognosis. In 2004, Spentzos et al.[85] 
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showed the positive prognostic behavior of a number of 115 
mRNAs present in 68 patients with ovarian cancers where 
the mRNA profiling data successfully could predict the sur-
vival rate of patients. In another genome-wide approach, De 
Sousa et al.[86] recruited 1100 patients with colorectal cancer 
where mRNA biomarkers successfully commented on the prog-
nosis of colorectal cancer. In a few other related studies, aber-
rantly expressed NOTCH1 mRNA was found to be interrelated 
with poor survival of patients with non-Hodgkin lymphoma[87] 
while Cyclin D1 and TS mRNA was linked with the poor sur-
vival of breast cancer patients.[16]
Compared to mRNA, miRNAs are more stable,[88] which 
explains their good prognostic behavior in cancer. Over the past 
several years, a large number of miRNAs have been reported as 
effective indicators for the cancer prognosis.[89–91] It was dem-
onstrated that overexpressed miR-21 was significantly linked 
with the poor prognosis and therapeutic outcome of patients 
with colon cancer,[89] while downregulated let-7 miRNA was 
correlated with poor survival of patients with lung cancer.[91] 
In another study, the expression pattern of miR-335 and miR-
126 were lost when the condition of patients with breast cancer 
deteriorated, suggesting their active role in poor metastasis 
free survival (i.e., survival till the metastasis is detected).[92] 
Apart from miRNAs, few of the recently discovered lncRNAs 
also showed fairly good prognostic behavior.[13] For example, 
Kogo et al.[90] studied the expression pattern of HOTAIR in 100 
tissue samples collected from colon cancer and compared them 
with the matched normal sample where substantial changes 
in HOTAIR expression was observed. This study was extended 
to test samples derived from liver cancer where a strong cor-
relation of upregulated HOTAIR with liver metastasis and 
poor disease prognosis were observed. In a similar approach, 
Liu et al.[93] detected the overexpression of DANCR lncRNA in 
colorectal cancer tissues compared to that of matched normal 
tissues and their expression was highly correlated with the his-
tologic grade and lymph node metastasis (Table 1 presents an 
overview of diagnostic and prognostic potentials of RNA bio-
markers in various cancers).
3.3. Contradictory Findings on Circulating miRNAs as a  
Biomarker: Critical Evaluation
Despite recent advances in miRNA biomarker research, circu-
lating miRNAs have not made the translation yet into the clinic, 
partly due to their contradictory specificity and inconsistent 
reproducibility issues as cancer biomarkers under different 
physiological and pathological conditions.[98–104] For example, 
Haider et al.[98] reviewed a total of 416 circulating miRNA bio-
markers in 57 noncancerous diseases and identified that the 
differential expression of the miR-16, -155, -21, -126, and -223 
biomarkers were not specific for any particular diseases, rather 
associated with at least 10 noncancerous conditions. Witwer 
et al.[99] also published an extensive review on circulating 
miRNAs and showed the poor specificity and reproducibility of 
circulating miRNA as potential cancer biomarkers. In another 
study, Leidner et al.[103] reviewed the irregular reproducibility 
of breast cancer related miR-21 and miR-155 biomarkers. Egidi 
et al.[100] also pointed out the poor specificity issue of circulating 
miRNA. They studied the expression level of miR-21 and miR-
141 in 38 prostate cancer patients after their radical prostatec-
tomy (i.e., surgical removal of prostate gland) and showed that 
serum samples collected from patients with no prostate glands 
had significantly elevated level of miRNAs. This finding raised 
the concern as to whether elevated levels of miR-21 and miR-
141 in samples of prostate cancer patients collected after their 
radical prostatectomy is indicative of prostate cancer or simply 
related to general disease states such as inflammation.
Although, the miRNAs role as a cancer biomarker is under 
careful consideration, it is widely accepted that various bio-
logical and technical pitfalls associated with miRNA studies, 
including lack of automation and standard workflows in labo-
ratories, inefficient sampling and extraction methods, and 
platform dependent variations could result in these incon-
sistencies.[37,101,102,105] One possible solution for avoiding this 
variation is to directly screen miRNA that is released from 
the tumor rather than screening whole plasma or serum. This 
could be achieved by screening the extracellular vesicles (e.g., 
exosomes) derived miRNAs which have the capability of repre-
senting parental tumor cells.[99]
4. Detection of RNAs: The Challenges
Despite the recent development of RNA detection methodolo-
gies, several major challenges still remain. These challenges 
involve the following considerations.
4.1. Stability of RNAs
RNA is generally unstable at room temperature due to the 
chance of ribonucleases (RNase) associated degradation. There-
fore, both endogenous and exogenous RNases can affect the 
accuracy of the detection via progressive degradation of the 
target RNA during incubation steps. One potential solution of 
this problem is the use of RNase inhibitor in the assay as dem-
onstrated by Frei et al.[106] In their multiplexed quantification 
assay for RNAs, referred to as PLAYR (proximity ligation assay 
for RNA), RNase inhibitor was used to avoid RNA degrada-
tion. This concern is not factual for RNAs available in various 
vesicles and biological molecules (e.g., exosomes and apoptotic 
bodies). The RNAs in these bodies are usually packaged into 
their structures (i.e., exosomal RNAs are protected by the mem-
brane structure of exosome) and thus become inaccessible to 
RNases.[63–65]
4.2. Sample Preparation and Choosing the Sample Source
The efficiency of RNA detection is heavily influenced by the type 
of sample source and preparation method.[102] Wang et al.[107] 
showed that the expression level miRNA can be different in 
serum and plasma of the same individual. They found that 
miRNA concentrations in serum were higher compared to the 
corresponding plasma samples of the same person. They sug-
gested that the presence of platelet-derived miRNAs originating 
from the blood coagulation process could be responsible for 
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this source-dependent variation. In another report, Leidinger 
et al.[108] showed that the influence of ethylenediaminetet-
raacetic acid (EDTA) on the expression and degradation of 
miRNA present in blood samples. EDTA has routinely been 
used as an anticoagulant in blood collection tubes for miRNA 
analysis in clinical settings. In this method, the sampling tubes 
were incubated with EDTA at different time intervals (0 min, 
10 min, and 2 h) after the blood draw from 6 healthy individ-
uals. It was observed that with increasing incubation time, the 
levels of miRNAs in the blood sample were significantly altered. 
The report suggested that transcription and degradation of the 
miRNAs in the white blood cells and platelets could still be 
dominating inside the sampling tube, causing a noticeable vari-
ation in the miRNA level derived from same individual under 
two different EDTA-incubation intervals. Therefore, the use 
of stabilizing reagents in the blood collection tubes is highly 
recommended to stop unexpected expression and degradation 
of miRNA (i.e., variations in miRNA expression level).[102]
4.3. Low Sensitivity due to Ineffective Extraction Methods
The readily available concentration of clinically relevant RNAs 
in tissues, serum, or other body fluids is very low. Therefore, 
a highly sensitive and specific method needs to be designed 
for extracting RNAs from body fluids. The RNA extraction 
method is also crucial because a little discrepancy in the anal-
ysis could result in false-positive responses. This observation 
was also evident from a study by McDonald et al.[109] who dem-
onstrated that the majority of variance in the RNA detection 
was derived from the extraction process used. Thus choosing 
the right extraction method along with careful optimization 
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Table 1. RNA biomarkers associated with diagnosis and prognosis of cancer.
Type of RNA Target Sample source and type RNA expression Diagnostic and/or prognostic RNA biomarkers Ref.
Messenger 
RNA (mRNA)
hTERT mRNA, EGFR 
mRNA
Lung cancer tissue and serum with healthy 
controls
Downregulated hTERT mRNA, combined with EGFR mRNA  
as both diagnostic and prognostic biomarker 
for pulmonary malignancies
[17]
ASAP1 mRNA 10 pairs of epithelial ovarian cancer (EOC) tissue 
and normal samples
Upregulated ASAP1 mRNA as prognostic marker of ovarian 
cancer
[93]
cyclin D1 mRNA Tissue samples from 151 patients  
with low-grade B-cell lymphoma
Upregulated in 128 
patients
Cyclin D1 mRNA as diagnostic marker  
of Mantle cell lymphoma (MCL)
[94]
Fusion mRNA TMPRSS2–ERG 
mRNA
Transgenic mice prostate Upregulated Diagnostic marker of prostate cancer [59]
microRNA 
(miRNA)
A number of 470 
human miRNAs 
screened
76 tumor and matched adjacent normal  
tissues derived from radical prostatectomy 
specimens
10 upregulated and 5 
downregulated
miR-96 as prognostic biomarker of prostate 
cancer
[95]
Global miRNA- micro-
array screening
A number of 123 lung cancer  
and matched normal tissues
35 upregulated and 3 
downregulated
Upregulated miR-21, miR-17-5p, miR-191,  
miR-128b, miR-199a-1 as diagnostic bio-
markers for lung cancer
[80]
Global miRNA- micro-
array screening
Tissues derived from 46 colon cancer  
and 8 normal individuals
21 upregulated  
and 1 downregulated
Upregulated miR-21, miR-17-5p, miR-191,  
miR-29b-2, miR-223, miR-128b, miR-24-1, 
miR-24-2, miR-155, miR-20a, miR-107, miR-32, 
miR-30c, miR-221, and miR-106a as positive 
indicators of colon carcinoma
[80]
A number of 8 
miRNAs screened
40 prostate cancer tissue with  
matched normal tissue samples
2 downregulated Downregulated miR-205, miR-214 as  
diagnostic marker for prostate cancer
[96]
Global miRNA micro-
array screening
79 breast cancer and 6 normal tissues 15 upregulated and 12 
downregulated
Upregulated miR-21, miR-17-5p, miR-29b-2, 
miR-146, miR-155, miR-181b-1 as diagnostic 
indicator of breast cancer
[80]
Microarray for 
screening total 389 
miRNAs
197 primary colon tumor and  
matched normal tissues
37 miRNAs dysregulated Upregulated miR-21 linked with the poor sur-
vival of patients with colon adenocarcinoma
[89]
Long 
noncoding 
RNA(lncRNA)
DANCR lncRNA 107 colorectal cancer tissues with  
paired adjacent normal tissues
upregulated Upregulated DANCR lncRNA as prognostic 
marker for colorectal caner
[93]
HOTAIR lncRNA 100 cancerous and matched  
noncancerous tissues collected from patients with 
colorectal cancer
upregulated Upregulated HOTAIR as prognostic marker for 
colorectal cancer
[90]
HOTAIR lncRNA Serum collected from patients with esophageal 
cancer (including 42  
tumor resection and 8 without surgery)  
and 20 healthy volunteers
upregulated Upregulated HOTAIR as potential diagnostic 
biomarker for esophageal cancer
[97]
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(i.e., incubation time, centrifuging speed, etc.) of the extraction 
steps is necessary for obtaining accurate detection.
4.4. Specificity Issues due to the Cross-Talk between RNAs
RNAs originating from the same family often share similar 
physicochemical properties and sequences.[110] Consequently, 
accurate and sensitive detection of RNAs is often compro-
mised by the background response from the closely related 
sequences of nontarget RNAs. Over the past several years, 
many approaches have been employed to address this issue. 
For example, Castoldi et al.[111] used a special type of thermo-
stable probe known as locked nucleic acid in microarray assay 
to specifically detect single base mismatch and closely related 
miRNA sequences. In another study, Labib et al.[43] used p19 
protein (p19 exclusively binds with double stranded miRNA) in 
an electrochemical assay to reduce the background responses 
from closely related nontarget sequences.
4.5. Nonspecific Response from Biomolecules
The clinical sample may have complex biological environments 
containing various unknown cells and biomolecules such as 
proteins, which could nonspecifically be attached on the sensor 
surface resulting in false-positive responses. Therefore, a suit-
able blocking agent such as mercaptohexanol, mercaptoethanol, 
poly(ethylene glycol), or bovine serum albumin can be used to 
prevent nonspecific bindings.[112]
4.6. Varying Size of RNAs
The length of RNA spans over very small (e.g., miRNA, 
18–20 nt) to large (e.g., lncRNA > 200 nt). Compared to longer 
RNAs, detection of short RNAs becomes challenging due to 
their size match with primers of amplification-based detection 
techniques. To address this issue, short RNAs can be enzy-
matically polyadenylated to produce longer sequences before 
the reverse transcription step in RT-qPCR via using oligo-dT 
primers.[113] Another possible way to avoid primer match with 
target RNA is to use a stem–loop primer during reverse tran-
scription, which formed a nicked RNA hybrid via hybridization 
with the 3′ end of the target RNA sequence.[114] On the other 
hand, the detection of long RNAs using hybridization-based 
approaches also a significantly challenging task. This could be 
explained by the fact that, due to the presence of an extra free 
oxygen atom in the additional ribose of the RNA structure, long 
RNAs are prone to interaction between nucleotides and often 
obtain secondary and tertiary structures[115,116] on the sensor 
surface, thereby minimizing the hybridization efficiency.
4.7. Physiological Variation in Humans
Natural variation in the expression levels of RNAs both between 
and within individuals is a considerable issue in RNA detec-
tion in clinical samples, which mostly could be the result of 
differences in gender, race, age, diet of individuals, etc. It has 
also been revealed that the variation is more when the sample 
size is small (<100 individuals), therefore the variation can be 
lessened by recruiting a large cohort of sample.[37]
5. RNA Biomarker Detection Technologies
5.1. Amplification-Based Molecular-Biology Techniques
Amplification-based nucleic acid detection methods such as 
RT-qPCR, microarrays, and RNA-seq have been widely used 
for RNA biomarker detection and expression analysis. In these 
methods, generally the RNA template is reverse transcribed 
to complementary DNA (cDNA) using an RT enzyme. RT is a 
RNA-dependent DNA polymerase enzyme that creates cDNA 
libraries from mRNA. cDNA is then further amplified by PCR 
or RNA-seq for detection purpose.[117,118]
5.1.1. RT-qPCR
RT-qPCR is a sensitive and widely used method for RNA anal-
ysis due to the advantages associated with the requirement of 
relatively less starting RNA, wide dynamic range, and better 
accuracy.[117] Over the past several decades, a great number of 
RT-qPCR-based RNA expression analysis methods have been 
developed and also commonly used in clinical trials.[31,32,78,110,119] 
In 2005, Chen et al.[114] developed one of the well-known methods 
for miRNA analysis, referred to as TaqMan miRNA assay 
(Figure 2I). In this method, a unique stem–loop reverse tran-
scriptase was adopted for cDNA conversion which was followed 
by TaqMan PCR analysis for the quantification of total 5 miRNAs 
present in mouse tissues. This method has since been extensively 
used to quantify miRNAs for different applications. The beautiful 
feature of this method is that it can differentiate closely related 
miRNA sequences having as low as one nucleotide difference. 
Mestdagh et al.[120] described a systematic approach to compare 
the analytical performance of twelve commercially available 
miRNA analysis platforms including RT-qPCR, microarray and 
RNA-seq. Among these methods, the RT-qPCR offers the highest 
sensitivity for the analysis of miRNA. Although RT-qPCR is sensi-
tive and efficient for measuring relative concentrations of RNA 
with respect to an internal standard, it has a limitation for the 
absolute quantification of RNAs.[102,120] Another potential weak-
ness of this method is that it usually works with a small number 
of expressed genes and, thus, is not suitable for high-throughput 
RNA screening.[117] It is also important to note that this method is 
effective for already established and prevalidated RNA biomarkers 
while microarray and RNA-seq methods are well-suited for the 
discovery and validation of novel RNA biomarkers[102,121,122]
5.1.2. Microarray-Based Methods
Being a relatively less expensive method, microarray-based 
assays can simultaneously profile a large number of RNAs and 
offer multiplexed analysis.[33] Typically a microarray comprises 
thousands of spots containing multiple oligonucleotides probes 
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on a platform, which hybridize with RNAs of interest for large-
scale expression analysis (Figure 2III).[33,123] A significant 
number of microarray-based methods have been developed for 
genome-wide analysis of RNAs.[33,34,86,123–125] In 2004, Rogler 
et al.[126] developed a reverse format microarray termed an 
RNA expression microarray (REM). In REM, total RNAs were 
initially reverse transcribed to produce a cDNA library. These 
cDNAs were then printed on a solid support of corning gamma 
amino propyl (GAP) slides. Humidified hybridization chamber 
containing mixed Cy3- and Cy5-labeled probes were designed 
to enable simultaneous hybridization of two genes. The appli-
cability of the REM was tested for the specific detection of 
albumin, Hnf-4 and Igfbp-1 and c-Myc expression. Zhu et al.[125] 
developed another method which detected aberrantly expressed 
303 lncRNAs and 565 mRNAs in Helicobacter pylori infected 
cells. Very recently, Hu et al.[127] reported anther microarray 
assay to explore the role of miRNAs in gefitinib (a common 
EGFR inhibitor available as cancer drug) resistance. By using 
the commercial Agilent miRNA-microarrays, they compared 
the miRNA expression of a gefitinib-resistant human cell line 
with its parental cell line (not resistant to gefitinib). The micro-
array profile revealed that the expression of miR-149-5p was 
altered in the gefitinib resistant cell line. Further RT-qPCR and 
biological function tests confirmed the potential involvement of 
overexpressed miR-149-5p in gefitinib resistance. The micro-
array method was also used to detect differential expression of 
ZEB1-AS1 lncRNAs in HCC,[128] where ZEB1-AS1 lncRNA was 
mostly upregulated in metastatic tumor tissues. Rui et al.[129] 
performed a microarray profiling of lncRNAs in lymph node 
metastasis of patients with colorectal cancer. They identified 
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Figure 2. Amplification-based molecular-biology techniques for RNA biomarker detection. I) A schematic of the TaqMan PCR method for the analysis 
of miRNA. Stem–loop RT primers anneal at the 3′ site of the miRNA targets and reverse transcribed to produce cDNA. Then, miRNA-specific forward 
and reverse primer and a dye-labeled TaqMan probe are used to quantify the amplified miRNAs. II) A graphical presentation of signal amplification by 
the ternary initiation complexes (SATIC) method for isothermal detection of RNAs. In SATIC, an initiation complex comprising target RNA, a circular 
DNA template, and a DNA primer is used for rolling circle amplification (RCA). First, the target RNA is hybridized with the complementary sequence of 
a circular DNA template. Then, a DNA primer starts the strand elongation by ϕ29 DNA polymerase to perform the rolling circle amplification at 37 °C 
for 2 h. The RCA-amplified-DNA products acquire secondary structures (known as Gquadruplex (G4) DNA). These G4s are stained with N3-hydroxyethyl 
thioflavin T (ThT-HE) and emit strong fluorescence, allowing the detection of target RNA in real-time. The method was further extended using two 
different initiation complexes to enhance the analytical performance. III) A schematic representation of a RNA microarray where the total extracted 
RNA acts as a template for reverse transcriptase for production of a cDNA library, which were printed on glass slides followed by probe hybridization, 
microarray scanning, and data processing. I) Reproduced with permission.[114] Copyright 2005, Oxford University Press. II) Reproduced with permis-
sion.[139] Copyright 2016, American Chemical Society. III) Reproduced with permission.[123] Copyright 2002, Nature Publishing Group.
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the dysregulation of a total of 1133 lncRNA transcripts in meta-
static lymph node, compared with normal lymph node. In 
another microarray study, a total number of 3146 differentially 
expressed lncRNAs and 2208 mRNAs in sinonasal squamous 
cell carcinoma with respect to noncancerous tissues were iden-
tified.[130] These demonstrations suggest that microarrays are 
more suitable as discovery tools.[37,121,122]
5.1.3. RNA-seq
The next-generation sequencing of RNAs (RNA-seq, also known 
as massively parallel cDNA sequencing) is one of the best alter-
natives to microarray and RT-qPCR-based methods and has 
gained a lot of interest in both small- and large-scale analysis 
of RNAs with greater sensitivity and specificity.[4,35,87,118] Apart 
from covering a relatively broad range of transcripts, it can also 
detect mRNA transcript at a single-nucleotide resolution.[118] 
However, as described by Tavallaie et al.,[37] RNA-seq method 
cannot always reliably quantify circulating miRNAs in a sample 
with highly varying miRNA distribution pattern.
5.1.4. RNA Detection by Isothermal Amplifications
RT-qPCR exponentially amplifies a small amount of target 
RNA using multiple heating steps (melting steps) during the 
thermal cycling which is not appropriate for the interrogation 
of RNA sequences in live cells.[131] To avoid this issue, iso-
thermal nucleic acid amplification strategies, which work at 
cellular temperatures could be an alternative choice for RNA 
detection. In the past decades, various types of isothermal 
amplification-based RNA detection methods have been intro-
duced including reverse transcription loop-mediated amplifi-
cation (LAMP),[132–134] RNA primed rolling circle amplification 
(RPRCA),[135,136] signal mediated amplification of RNA tech-
nology,[137] and strand displacement amplification.[138]
RT-LAMP is a one-step isothermal amplification method 
that generally provides up to 108-fold amplification of single 
target RNA sequence in 1 h using a single tube. It uses a set 
of specially designed primers in combination with the mixture 
of DNA polymerase and RT.[134] The amplified RNA products 
can then be detected by a suitable readout method (e.g., visu-
alization with SYBR Green I stain). Horibe et al.[132] developed 
an RT-LAMP-based assay for detecting lymph node metas-
tasis in gastric carcinoma patients. In this method, RNA was 
extracted from 92 lymph nodes samples of 9 patients with 
gastric cancer followed by the isothermal amplification of 
cytokeratin19 (CK19) mRNA. Among 92 lymph nodes samples, 
15 were found to be metastasis-positive, which were further 
validated with a nested RT-PCR assay. Although the sensitivity 
of RT-PCR and RT-LAMP is similar, the analysis time in RT-
LAMP is much faster. On the contrary, the RPRCA method 
uniquely uses RNA primers instead of DNA primers to avoid 
the use of reverse transcriptase for detecting small RNAs in a 
single tube.[135] In RPRCA, usually the target RNA hybridizes to 
its complementary sequence on a circular DNA template, and 
is then cleaved by RNase H (30 °C) followed by elongation (via 
ϕ29 DNA polymerase at 30 °C), amplification, and detection 
steps.[135,139] In 2016, Fujita et al.[139] developed another RCA-
based method referred to as signal amplification by ternary 
initiation complexes (SATIC) (Figure 2II). In SATIC, a ternary 
initiation complex was formed among the RNA, circular DNA 
template, and a DNA primer, followed by RCA at 37 °C. This 
caused the amplified products to acquire secondary structures 
producing multiple copies of Gquadruplex (G4) DNA. The G4s 
were fluorescence-stained with N3-hydroxyethyl thioflavin T 
(ThT-HE) for the real-time detection of RNA. The method was 
further improved using two different ternary initiation com-
plexes in the RCA process to enable the visual observation.
5.2. RNA Biosensors
Rapid advancements in nanotechnology have led the develop-
ment of novel biosensor strategies. Typically an effective bio-
sensor is composed of two major components: i) a receptor 
(biomolecular recognition species), which specifically recog-
nizes the target analyte, and ii) a transducer (signal-generating 
and enhancing element) that recognizes the biomolecular 
interaction and converts this interaction into a measurable 
signal.[37,140] Over the past several years, several novel biosen-
sors comprising nanopore, optical, and electrochemical read-
outs have extensively been developed for the quantification and 
analysis of RNA biomarkers. Starting with a brief outline of 
optical and nanopore-based biosensors, the remaining part of 
the review highlights the existing electrochemical sensors.
5.2.1. Optical Sensors
Until now, miRNAs, mRNAs, and rRNAs were reported to be 
analyzed and quantified by optical biosensing strategies where 
surface plasmon resonance (SPR) and surface enhanced Raman 
spectroscopy (SERS) readouts have mostly been employed.[39] In 
SPR, surface immobilized molecular interaction between target 
RNAs and specific bioreceptor causes a change in the refrac-
tive index ,which is measured by the transducer in real-time. It 
can also explain the molecular interaction of RNA on sensor via 
analyzing binding kinetics.[39] Sipova et al.[141] developed a label-
free and portable SPR sensor to detect miR-122 from mouse 
liver tissue. In this method, an additional amplification step 
was used where the captured miRNA was subsequently rec-
ognized by an antibody to enhance the sensitivity of the assay 
(detection limit was 2 × 10−12 m). The assay (35 min) was rela-
tively rapid. More recently, Huertas et al.[142] designed another 
SPR sensor for quantifying cancer-specific alternatively spliced 
variants of Fas mRNA (Figure 3). This approach is comparable 
with RT-qPCR in terms of sensitivity and reproducibility. The 
method is also highly specific due to the use of formamide 
which significantly reduced the chance of cross hybridization 
between variants of Fas mRNA. It also uniquely incorporated a 
sample fragmentation step using RNA alkaline hydrolysis prior 
the readout to avoid accessibility problems of long mRNA iso-
forms. The viability of the method was further tested in HeLa 
cancer cell lines.
On the other hand, SERS-based methods depend on the 
quantification of surface plasmon excitation in metallic 
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nanostructures of SERS substrates, which has been used 
for analyzing different RNA biomarkers including fusion 
mRNA.[143–145] Very recently, Wang et al.[143] demonstrated the 
application of a “turn-on” SERS method referred to as “inverse 
Molecular Sentinel (iMS)” nanoprobes, for multiplexed detec-
tion of miRNAs. In this method, the SERS probes used plas-
monic-active nanostars as the sensing platform where the 
“OFF-to-ON” signal switch relied on the conformational change 
of stem–loop (hairpin) capture probes during target hybridi-
zation. The clinical applicability of the assay was tested in 
breast cancer cell lines using a mixture of the two differently 
labeled nanoprobes to detect miR-21 and miR-34a biomarkers 
respectively.
In 2007, Seferos et al.[146] introduced a fluorescence method 
for mRNA analysis which used a novel intracellular RNA probe 
termed as “Nanoflares.” Nanoflares has the unique feature of 
transfecting into the live cells for visualizing and quantifying 
mRNA. First, 13-nm gold nanoparticles (AuNPs) were function-
alized with thiolated oligonucleotides (acting as the recogni-
tion element for mRNA transcripts) to develop the nanoflares. 
Then, a short reporter sequence tagged with cyanine (Cy5) 
dye was hybridized with functionalized AuNPs. This reporter 
sequence was considered as “flares” in the nanoflares sensor. In 
the absence of target, the Cy5 dye is quenched due to proximity 
to the AuNP surface. However, when target RNA is present, 
a robust duplex is formed between the RNA and nanoflares 
which causes the removal of flare from the AuNP, providing 
measurable fluorescence readout. The method was success-
fully tested in a synthetic target and a real sample for the real-
time quantification of mRNA. One obvious disadvantage of the 
existing transfecting agents (e.g., lipids and dendrimers) for 
RNA analysis is that they can produce toxicity inside the cell. 
Furthermore, oligonucleotides-based transfecting agents are 
unstable inside the live cells due to their enzymatic degrada-
tion, primarily via the action of 3′ exonucleases. This instability 
of oligonucleotides inside the live cell and other associated 
issues were critically reviewed by Opalinska et al.[147] Nano-
flares, on the contrary, are not toxic and are highly stable inside 
the cells. Nanoflares thus have very high potential in detecting 
RNAs from live cells and have already been incorporated in sev-
eral RNA biosensing approaches.[148,149]
5.2.2. Nanopore Sensors
Nanopore sensing tools are one of the most prominent single-
molecule sensors. Typically, in the presence of a conducting 
fluid, when a potential is held, nanopores produce electric cur-
rent due to the charge transport in the holes. The produced 
current is highly sensitive to the size and physical properties 
of the pore. Thus, detectable current changes can be observed 
when the target analyte (e.g., RNA) is trapped inside the pore 
after hybridization with a target specific capture probe.[150,151] 
Until now, only miRNAs have been interrogated via nano-
pores.[152–155] Wang et al.[155] developed a unique nanopore 
sensor using α-hemolysin protein pore (Figure 4). The method 
relied on the translocation of single-stranded oligonucleotides 
through the 2 nm sized pore functionalized with a program-
mable oligonucleotide probe. Both ends of this oligonucleotide 
probe were attached with a poly (dC)30 signal tag, which then 
became highly specific for target miRNA and thus avoided 
their cross-hybridization with nonspecific RNAs. Depending 
on the presence of specific miRNA, a measurable signal was 
obtained. The method also showed highly sensitive detection 
limit of 100 × 10−15 m. Additionally, the sensor was success-
fully tested to differentiate the relative levels of miR-155 of 
healthy and lung cancer patients. A comparative analysis of the 
advantages, disadvantages, and analytical functionalities of the 
nanopore sensors along with other major RNA detection plat-
forms[39,102,123,152,154,156–161] is summeaized in Table 2.
5.2.3. Electrochemical Biosensors
In recent years, significant progress has been made toward 
the development of electrochemical methods to interrogate 
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Figure 3. Real-time and label-free analysis of alternative spliced variants of Fas mRNA by an SPR sensor. Purified total RNA, extracted from HeLa cells, 
is passed through two specially designed SPR channels. Each channel is functionalized with one DNA-probe, which is complementary to the splice-
junctions of the Fas gene isoforms (either Fas567 or Fas57). Under optimized functionalization and detection conditions, real-time binding of the 
targets and the resulting change in the refractive index are monitored. Reproduced with permission.[142] Copyright 2016, Elsevier.
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Figure 4. A schematic diagram of lung-cancer-related single-miRNA-molecule (miR-155) capture by a nanopore. a) A microRNA (red) hybridized to a 
probe (green) having signal tags on both ends. b) Diagram of current blocks in the nanopore, in the presence of 100 × 10−9 m miR-155 and its capture 
probe P155 on the cis side of the pore. The red boxes denote the multilevel current pattern resulting from the hybridization of target miR-155 with the 
capture probe. c) A typical multilevel long block of hybridized miR-155 at +100 mV. Right panel: molecular mechanism of hybrid dissociation and 
translocation. Level 1: Capture of the target-probe hybrid, unzipping of the target miRNA from the probe followed by the translocation of the probe. 
Level 2: Unzipped microRNA staying inside the pore. Level 3: Translocation of the unzipped microRNA through the pore. Lower panel: multilevel cur-
rent blocks at +150 and +180 mV where the duration of Levels 1 and 3 is decreased with increasing the potential supporting the functionality of the 
nanopore model. d) Quantification of miR-155 levels detected by RT-qPCR in trans solutions once the electrical readout is taken. e) A single-level block 
(from (b)) generated by a trapped miR-155-probe hybrid (without unzipping and translocation). f) A spike-like short block generated by the transloca-
tion of unhybridized miR-155 or probe from the cis solution. Reproduced with permission.[155] Copyright 2011, Nature Publishing Group.
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clinically relevant RNAs.[37,40,44,161] Most of these methods are 
based on the hybridization of target RNA sequences to the sur-
face bound complementary receptor probes (mostly DNA oligo-
nucleotides) on the electrode. The hybridization of RNAs with 
probes results in a measurable electrochemical signal. Here, 
signal transduction relies on various factors including intrinsic 
electroactivity of nucleobases, and the presence of redox indi-
cators (e.g., intercalators such as methylene blue), covalently 
bound redox labels (e.g., nanoparticles), or reporter enzymes 
(e.g., phosphatases, peroxidases).[40,162] Then, the detection 
of RNAs is mostly read via voltammetric, amperometric, and 
impedimetric approaches.[40,163] In parallel to these, few ultra-
sensitive electrochemical approaches have also been developed 
using chip-based nanostructured microelectrodes for multi-
plexed detection of RNA biomarkers.[161,164,165] In these chip-
based sensors, nanostructured electrodes are usually deposited 
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Table 2. Major detection platforms for RNA biomarkers.
Detection platform 
or assay
Detection principle Advantages Disadvantages Amount of RNA 
required or 
LOD
References
Quantitative reverse  
transcription PCR 
(RT-qPCR)
Reverse transcription of RNAs to cDNA  
followed  
by quantitative PCR
Established method, sensitive, specific, 
sensitive, ideal for small RNAs, widely 
available and compatible with laboratory 
workflows,
Expensive, not suitable 
for high throughput RNA 
screening and discovery 
studies, effective only 
against established RNAs
Input RNA,  
<ng or ng–μg
[102,156,157]
Microarray Hybridization of RNA with complementary 
probes  
prefabricated in the thousands of spots  
on a microarray platform
Established method, relatively inexpensive, 
high throughput screening, suitable for 
discovery studies
Relatively lower specificity 
and sensitivity, no 
absolute quantification, 
cannot efficiently dis-
criminate closely related 
miRNAs
Input RNA, 
ng–μg
[102,123,156,157]
RNA sequencing Preparation of cDNA library from target  
RNAs followed by “massively parallel” 
sequencing  
of library derived cDNA
Can distinguish miRNAs from closely 
related RNAs and precursors
Extensive bioinformatics 
supports required, 
suitable only for relative 
quantification
Input RNA,  
ng–μg > ng
[102,123,156,157]
Surface Plasmon 
resonance  
(SPR)
Measurement of refractive index (RI) 
changes resulting  
from the surface  
immobilized molecular interaction between 
RNAs and bioreceptor
Real-time and label- free analysis Low throughput, higher 
sample input, longer 
assay time
Input RNA, 
ng–μg
[39,158]
Nanopore The charge transport in the nanopore is 
halted in the  
presence RNA target of interest. The resul-
tant blockade  
current is quantified
Sensitive, single molecule sensor Complicated sensor fab-
rication, not suitable for 
detecting long RNAs
Input RNA, 
ng–μg
[152,154]
Electrochemical 
sensors
a) Cisplatin–biotin labeled mRNA/redox 
polymer bilayer on a gold electrode. Enzy-
matic oxidation of glucose oxidase–avidin 
molecules produce detectable amperometric 
signal
a) Amplification free, highly sensitive, low 
sample input (5 ng)
a) Multistep sensor 
fabrications
a) LOD, 0.05 × 
10−15 m
[159]
b) Target mRNA induced conformational 
change of hairpin (HP) probe results in a 
readable electrochemical signal
b) Amplified signal, efficient capture (HP 
probe is thousands fold sensitive than 
linear capture probe)
b) Not tested in complex 
biological sample
b) LOD, 0.4 × 
10−15 m
[160]
c) Target fusion mRNA is captured on amino 
acid/nucleic acid chimeras (ANAs) capture 
probe functionalized gold microelectrodes. 
Voltammetric readings enable the detection 
in the presence of [Ru(NH3)6]3+/[Fe(CN)6]3− 
redox probe
c) Simultaneous screening multiple RNA 
targets, ANA capture probe facilitates low 
background response and stable mono-
layer formation on microelectrodes
c) Complicated and mul-
tistep sensor fabrications
c) LOD, 1.0 pg 
μL−1
[161]
d) Direct adsorption of magnetically cap-
tured target fusion RNAs on the unmodified 
screen-printed gold electrodes via RNA-gold 
affinity interaction. Resultant coulombic 
repulsion between negatively charged RNA 
and ferricyanide ions produce detectable 
voltammetric signal.
d) Significantly simplified sensor, avoids 
conventional surface modification and 
probe immobilization steps on electrode, 
relatively inexpensive, highly specific, 
amplification free, noninvasive screening
d) Not suitable for long 
RNAs
d) Target fusion 
mRNA can be 
detected from 
minimum 10 
cancer cells
[41]
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on the surface of the chip using photolithography which work 
as specific detector for multiplexed analysis.
Electrochemical Biosensing of Coding RNAs: Due to the cru-
cial role of coding RNAs (i.e., mRNA) in disease diagnosis 
and prognosis, several novel electrochemical sensors aiming 
to detect and analyze mRNA biomarkers have been devel-
oped.[40,41,159–161,166–168] One of the earliest mRNA-detection 
methods was demonstrated by Xie et al.[159] (Figure 5I). In 
this method, first, total extracted RNA was directly labeled 
with cisplatin–biotin and allowed to hybridize with a thiolated 
oligonucleotide capture probe, which was functionalized on a 
gold electrode. Following hybridization of target mRNA on the 
electrode surface, glucose oxidase–avidin molecules were intro-
duced in the system which conjugated with biotinylated target 
mRNA via the biotin–avidin interaction. Then, the electrode 
surface was coated with a cationic redox polymer containing 
osmium-bipyridine. Since the target mRNA is attached with 
glucose, the current generated from enzymatic oxidation of glu-
cose was directly proportional to the target mRNA concentra-
tion in the sample. The viability of this highly sensitive method 
was tested for the detection of GAPDH and cancer-specific p53 
mRNA (LOD, 0.5 × 10−15 m). Moreover, a partially complemen-
tary capture probe (single base mismatch) was introduced in 
the sensor, which produced notable drop in the amperometric 
response, supporting the excellent specificity of the assay.
The hairpin (HP) DNA probe is one of the most versatile oli-
gonucleotide probes for biomarkers screening and is commonly 
being used in optical and electrochemical assays for RNA 
detection.[160] The loop area of the hairpin probe is selectively 
designed to be complementary to the target RNA sequences. 
When RNA is hybridized with the HP probe, the stem loop 
structure of the HP opens up allowing the prefunctional-
ized electroactive reporter molecule to interact, resulting in a 
detectable signal. For example, Wei et al.[160] incorporated an 
HP probe on a gold electrode in a “signal on” electrochemical 
method and successfully detected interleukin (IL)-8 (a potential 
noninvasive biomarker for oral cancer) mRNA from saliva. In 
this approach, the 3′ end of the HP probe was tagged with a 
fluorescein molecule while the 5′biotinylated end was immo-
bilized on the streptavidin modified gold electrode to give the 
probe a stem loop structure. In the absence of target mRNA, 
resultant steric hindrance inhibits the binding of the anti-fluo-
rescein-HRP conjugate on the electrode surface thereby ceasing 
further reaction. When target mRNA is present, the hairpin 
opens up and then, in the presence of the TMB substrate, the 
bound HRP produces an amplified electrochemical signal. This 
signal is directly correlated with the amount of target mRNA 
present in the sample. The method was relatively fast and 
attained very high sensitively (≈0.4 × 10−15 m). The method was 
later extended for the multiplexed detection of mRNA.[167] In a 
similar approach, a switchable “on–off–on” technique involving 
a stem–loop oligonucleotide probe was used for the detection of 
tumor-specific survivin mRNA.[169]
One of the foremost challenges of RNA biomarker detection 
in clinical application is to simultaneously screen the very low 
amount of readily available RNA biomarkers in complex hetero-
geneous samples, which could contain many nonspecific tar-
gets. These challenges could be addressed via the multiplexed 
and highly sensitive analysis of RNAs by employing novel 
nanostructured electrochemical sensors.[161,164,165] For example, 
Vasilyeva et al.[161] developed a sensor for the analysis of cancer-
specific mRNA fusion using an array of nanostructured gold 
microelectrodes. In this method, a novel capture probe, termed 
as amino acid/nucleic acid chimeras (ANAs), was immobi-
lized onto the surface of microelectrodes. ANAs significantly 
enhance the assay performance compared to the existing 
neutral capture-probe-based assay. This is due to the fact that 
ANA has relatively good solubility along with the ability of 
forming stable monolayer on the sensor. The ANA also specifi-
cally can recognize and binds at the junction of gene fusion. 
In the presence of [Ru(NH3)6]3+/ [Fe(CN)6]3− redox probe, the 
concentration of hybridized mRNA was measured from the vol-
tammetric readout. To illustrate the applicability of the sensor, 
chronic myeloid leukemia specific BCR-ABL mRNA fusion was 
detected in cancer cell lines. When very high concentration of 
the partially complementary capture probe was used along with 
the fully complementary BCR-ABL probe, the electrochemical 
signal for the complementary targets was unaffected, showing 
the high specificity of the assay.
Apart from BCR-ABL, several other fusion mRNAs (e.g., 
TMPRSS2-ERG) have attracted significant interest as cancer 
biomarkers due to their role in cancer development and high 
specificity (Mertens 2015).[170] Fusion mRNA is transcribed 
from fusion gene as the product of chromosomal rearrange-
ments such as translocations, insertions, inversions, and 
interstitial deletions where two genes from each side of chro-
mosomal breakpoint may fuse together.[170,171] In addition, the 
coding sequences in one gene can be juxtaposed with the regu-
latory sequences of another gene to form the fusion gene.[170] 
Approximately 20% of all types of human cancers are associ-
ated with the fusion mRNAs.[172] For example, the TMPRSS2-
ERG fusion mRNA (originated from mutation between the 
TMPRSS2 promoter sequence and the ERG coding sequence) 
is uniquely expressed in ≈50% of malignant prostate cancer 
cases and considered as one of the finest selective biomarkers 
of prostate cancer for their aberrant role in the inhibition of the 
apoptosis of prostate gland cells.[59,173]
More recently, Koo et al.[41] have developed an amplification-
free method for detecting prostate cancer specific TMPRSS2: 
ERG mRNA fusion (Figure 5II). This method avoids the com-
plicated chemistries underlying the conventional multistep 
sensor fabrication steps thereby significantly simplifying the 
sensor design. Moreover, the method recruited patients’ urine 
samples to extract the TMPRSS2: ERG mRNA for electrochem-
ical interrogation, which offered a significant improvement in 
the noninvasive screening of prostate cancer patients. In this 
method, first, RNA was extracted and purified from patient 
urine samples. TMPRSS2: ERG mRNA transcripts were then 
selectively captured by the biotinylated capture probe in the 
solution. Next, streptavidin-coated magnetic nanoparticles were 
dispersed into the reaction mixture. After magnetic purifica-
tion, the captured mRNA fusion was directly adsorbed on the 
commercially available screen-printed gold electrodes via the 
RNA–gold affinity interaction.[174] The adsorbed mRNA (nega-
tively charged) creates higher Coulombic repulsion toward 
the negatively charged ferricyanide ions thereby resulting in a 
decreased electrochemical signal compared to that of control 
and normal sample. The method showed excellent specificity in 
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detecting TMPRSS2: ERG mRNA while a negative control cell 
line (TMPRSS2: ERG fusion gene absent) was used. Until now, 
the most preferable approach for identifying cancer associated 
fusion transcripts is the next-generation sequencing (NGS), 
especially RNA-seq.[171] However, the detection of fusion mRNA 
by RNA-seq has been limited by the resultant false-positives 
response.[118,175,176] Moreover, RNA seq for fusion mRNA 
heavily relies on the complicated data analysis procedure with 
various type of software packages. This was also supported by 
a recent study from Kumar et al.[176] who observed substantial 
variation in the NGS data analyzed by different fusion-mRNA-
detection software tools. In this regard, the amplification-free 
Small Methods 2017, 1, 1700131
Figure 5. Electrochemical detection of coding RNAs. I) Schematic illustration of an mRNA detection assay using an mRNA/redox polymer bilayer 
model: cisplatin–biotin labeled mRNA is hybridized with a thiolated oligonucleotide capture probe functionalized on a gold electrode. Glucose oxi-
dase–avidin molecules are then introduced in the system, which binds the biotinylated target mRNA via a biotin–avidin interaction. Then, the electrode 
surface is coated with a cationic redox polymer which mediates the enzymatic oxidation of glucose. As the target mRNA is attached with glucose, 
the amperometric current generated from its oxidation is directly proportional to the mRNA concentration in the sample. II) Steps involved in an 
amplification-free detection of prostate-cancer-specific TMPRSS2:ERG mRNA using the mRNA–gold affinity interaction: a) TMPRSS2:ERG mRNA is 
the fusion between the TMPRSS2 promoter sequence and the ERG coding sequence; b) total RNA is extracted from urine samples followed by specific 
capture of TMPRSS2:ERG mRNA via a biotinylated capture probe. The target is then magnetically isolated from the sample pool using streptavidin-
coated magnetic beads; c) the magnetically captured target mRNA is heat-released and adsorbed on an unmodified screen-printed gold electrode. The 
presence of mRNA is analyzed by differential pulse voltammetry in the presence of the [Fe(CN)6]4−/3− redox system. I) Reproduced with permission.[159] 
Copyright 2004, American Chemical Society. II) Reproduced with permission.[41] Copyright 2016, American Chemical Society.
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and nonenzymatic electrochemical method has clear advan-
tages over RNA-seq for acquiring relatively accurate detection 
of fusion mRNAs.
Electrochemical Biosensing of Regulatory RNAs (Non-
coding RNAs): The principle of electrochemical biosensing 
of miRNAs is almost the same as that of DNA or mRNA 
hybridization biosensors. One example of miRNA detection 
strategies is the direct oxidation-based analysis of circulating 
miRNA bases.[177] In this method, miR-122 was hybridized 
with its inosine substitute capture probe on a carbon-based 
nanostructured electrode. Electroactive polymers were also 
used on the electrode to increase the electroactive area and 
reduce the electrical resistance. Then, direct oxidation of 
guanine during RNA hybridization resulted in a measurable 
differential pulse voltammetric (DPV) signal. This method 
significantly improved the limit of detection of circulating 
miRNAs in serum (10 × 10−15 m). The detection limit was 
further improved (100 × 10−18 m) in patient serum via the 
development of a DNA-concatemer-based ultrasensitive 
electrochemical method.[178] In this approach, two auxiliary 
probes were self-assembled to form a one-dimensional DNA 
concatemers. An HP capture probe was immobilized on the 
surface of screen-printed gold electrodes. In the absence 
of target miR-21, the HP probe retained its loop structure 
offering no binding site for the DNA concatemers. This pro-
duced little electrochemical signals. However, when miR-21 
was present, the stem–loop structure of the HP capture 
probe opened up, allowing their hybridization with DNA 
concatemers. Next, the RuHex signal reporter bound to the 
negatively charged DNA concatemers on the working elec-
trode significantly amplified the electrochemical signal ena-
bling the detection.
Different intermediates of miRNA biogenesis such as pri-
miRNA, pre-miRNA, and other small noncoding RNAs such 
as rRNA share sequence similarities with miRNAs. During 
miRNA detection, these nonspecific RNA molecules can inter-
fere with the target miRNA via cross-hybridization resulting 
in false-positive response.[179] This issue was addressed via the 
incorporation of a special RNA binding protein known as p19 
in the sensor.[180] Usually, the p19 protein works as a molec-
ular caliper of small double-stranded RNA (21–23 base pairs) 
and isolates miRNAs in a size-dependent and sequence-inde-
pendent manner. Being more specific, the p19 protein does not 
bind to ssRNA, rRNA, mRNA, ssDNA, or dsDNA whereas it 
can specifically bind to the double-stranded miRNA.[179] Thus 
the inclusion of p19 in the reaction mixture can significantly 
reduce the chance of nonspecific detection. Using this exclusive 
property of p19 protein, a three-mode electrochemical sensor 
was developed for the detection of circulating miRNAs.[43] A 
schematic representation of this three-mode sensor is pre-
sented in Figure 6. The three-way analysis detects one or mul-
tiple miRNAs on gold-nanoparticle-modified screen-printed 
carbon electrodes by using square wave voltammetry (SWV) in 
the incubation buffer containing K3[Fe(CN)6] and [Ru(NH3)6]
Cl3. In the first modality, the hybridization of the target miR-21 
to its complementary thiolated-immobilized probe causes 
a modulation of the SWV signal (Figure 6b). A linear range 
of detection was found from 1 × 10−15 m to 10 × 10−12 m. In 
the second modality, the p19 protein dimer was added to the 
formed hybrid. This amplifies the SWV signal and allows an 
ultrasensitive detection of the miR-21 (i.e., linear detection 
range to 10 × 10−18 m to 10 × 10−15 m) via binding of the bulky 
p19 protein and consequently shielding the electrode surface 
(Figure 6c). In the third modalities, a universal displacement-
based sensor is formed on the basis of the self-assembled thi-
olated RNA probe bound to the saturation concentration of 
a miRNA, whereas the p19 is attached to the formed hybrid. 
Subsequently, a mixture of a new target miRNA (here miR-200) 
and its complementary nonthiolated-RNA probe is incubated 
with the p19-modified sensor. Because the nonthiolated-RNA 
probe is complementary to the miR-200 sequence, a newly 
formed hybrid at relatively higher concentration compared to 
the concentration of the immobilized hybrid can force the p19 
protein to dissociate from the immobilized hybrid on the elec-
trode surface, and to bind to the newly formed hybrid causing 
a shiftback of the SWV signal (i.e., the linear detection range 
to 100 × 10−12 to 1 × 10−6 m). This displacement-based sensor 
can therefore be employed for detection of any type of miRNA 
without the need of a thiolated capture probe (Figure 6d). 
Moreover, the sensor can distinguish miRNAs with different 
A/U and G/C content and differentiate single base mismatch 
in miRNAs.
The emerging functional insights of long noncoding RNAs 
in gene regulation has triggered extensive studies in the 
translational clinical research field.[12,26,51,84] Despite the huge 
clinical significance of lncRNAs, their electrochemical detec-
tion is not well explored. Until now, only a few reports on 
electrochemical biosensing of lncRNAs are available.[181,182] 
This could be explained by the fact that lncRNA has a rela-
tively long sequence with a high molecular weight. Moreover, 
due to the presence of an extra oxygen atom in RNA sugar, 
lncRNAs tend to interact with the nucleic acid backbone via 
hydrogen bonding, resulting in secondary or tertiary struc-
tures (i.e., hairpin, triplexes, and quadruplexes structures). 
Taken together these issues, the commonly used RNA-hybrid-
ization-based electrochemical sensors cannot recognize and 
effectively capture the target lncRNAs on the electrode surface. 
In 2015, Liu et al.[182] used the catalytic amplification ability of 
single-wall carbon nanotubes coated with Au–Rh hollow nano-
spheres (Au/Rh-HNP@SWCNT) to detect nuclear paraspeckle 
assembly transcript 1 (NEAT1) lncRNA, which is reportedly 
overexpressed in patients with HIV. The nanospheres have the 
combined benefits of RNA binding features of gold, unique 
electronic properties, and large edge-plane-to-basal-plane 
ratio of single-wall carbon nanotubes (SWCNTs), and the sur-
passing catalytic properties of Rh. In this sensor, the gold (Au) 
electrode was first modified with L-cysteine followed by the 
formation of a Au monolayer by the electrodeposition of an 
L-cysteine-containing gold electrode in a colloidal solution of 
Au nanoparticles. The nanomaterial (Au/Rh-HNP@SWCNT 
complex) tagged capture probe (RNA fragment containing a 
(GGGG) quadruplex) was then allowed to bind with each pos-
sible site of AuNPs. To avoid nonspecific binding, the sensor 
was soaked with hexanethiol. Finally the sensor was incubated 
with hemin solution where quadruplex containing target RNA 
binds with hemin resulting in a higher (catalytic) redox signal 
of hydrogen peroxides in the presence of HRP, allowing the 
quantification of NEAT1.
Small Methods 2017, 1, 1700131
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6. Conclusions
Here, we have provided an overview of the current progress of 
RNA-detection technologies with special emphasis on the devel-
opment of electrochemical biosensors. The major challenges 
involved in these strategies along with the diagnostic and prog-
nostic significance of clinically relevant RNAs have also been 
discussed. It has been shown that tumor-derived circulating 
RNAs can work as a liquid biopsy for the minimally inva-
sive diagnosis of cancer, resulting in less patient discomfort. 
Although, their high stability in clinical samples has triggered 
huge interest, necessary caution should be taken to ensure the 
minimal sample preprocessing of these RNA biomarkers to 
retain their high stability.
From the representative examples of different detection tech-
nologies, it is apparent that RNA biosensors usually involve 
the hybridization of target RNA with a capture probe followed 
by a suitable readout method such as electrochemical readout. 
Despite the significant progress made in these electrochemical 
methods, still major work needs to be performed to achieve a 
biosensor suitable for a point-of-care platform. This is because 
most biosensors are merely proof-of-concept demonstrations 
and highly dependent on complex sensor fabrications and a 
series of optimization steps in a well-equipped laboratory set-
up. To translate these laboratory-based proof-of-concept dem-
onstrations to clinical applications in real-world settings, there 
are many outstanding hurdles. One of the major issues is the 
false-positive detection of RNAs due to nonspecific bindings. 
To avoid this, an optimized sample extraction protocol and 
the development of innovative sensors are urgently required. 
Nonetheless, we have seen that several unique methods have 
attempted to address these requirements. For example, novel 
capture probes such as peptide nucleic acid analogs and micro-
engineered-electrodes-based electrochemical sensors have been 
designed to avoid cross-hybridization and increase the hybridi-
zation efficiency of RNAs where P19 protein was particularly 
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Figure 6. Three-mode electrochemical biosensor for multiple miRNA detection: first: a) a thiolated capture probe complementary to the target miR-21 
is self-assembled onto a gold-nanoparticle-modified screen-printed carbon electrode; b) the target miR-21 is hybridized with the thiolated probe causing 
an enhancement of the square wave voltammetric current (SWV); second: c) the binding of the p19 protein dimer to the formed hybrid attenuates 
the SWV signals due to the shielding the electrode surface; and third: d) in the presence of a newly formed hybrid between the target miR-200 and its 
nonthiolated complementary probe at high concentration, p19 protein is dissociated from the immobilized hybrid on the electrode surface and to bind 
to the newly formed hybrid causing a shiftback of the signal. Electrochemical measurements were performed in the incubation buffer containing 4 × 
10−3 m K3[Fe(CN)6] and 10 × 10−6 m [Ru(NH3)6]Cl3. Reproduced with permission.[43] Copyright 2013, The American Chemical Society.
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employed to remove nonspecific targets.[43,161] Moreover, a 
simplified electrochemical sensor using direct interaction of 
target RNA and gold electrode has also been developed to cir-
cumvent the multisteps sensor fabrication steps.[41] We have 
also observed the recent trends of using novel nanomaterials 
to accelerate the signal transduction and obtain amplified and 
sensitive detection signal.[182] Despite the rapid advances in 
the biosensing of mRNAs and circulating miRNAs, develop-
ment of electrochemical sensor for lncRNAs detection is still 
in its infancy. Considering their huge clinical potentials, more 
attention needs to be given to develop an effective and reliable 
biosensor for lncRNAs. We believe that the ultimate require-
ment for transforming the current approaches to point-of-care 
platform is the development of fully automated and integrated 
biosensors capable of high-throughput screening of RNA bio-
markers in a heterogeneous clinical sample. As highly efficient 
RNA biosensors have continued to develop, we foresee that an 
ideal RNA biosensor with desired clinical applications will be 
developed in near future.
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